Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
DBS Expects Slight Dip in 2026 Net Profit After Q4 Earnings Miss on Lower Interest Margins 
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
Anta Sports Expands Global Footprint With Strategic Puma Stake 
Indian Refiners Scale Back Russian Oil Imports as U.S.-India Trade Deal Advances 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
Washington Post Publisher Will Lewis Steps Down After Layoffs 
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
ALISO VIEJO, Calif., March 09, 2017 -- NVISION Eye Centers – a national leader in ophthalmic treatments and services, is pleased to announce the introduction of Avedro Photrexa® Viscous, Photrexa® and the KXL System used in corneal collagen cross-linking for the treatment of keratoconus. The procedure has the ability to both stabilize and strengthen the cornea, halting or slowing the progression of keratoconus in the early phases of the condition. It can also improve vision in some patients with a more progressed stage of the condition.
“Keratoconus is a progressive thinning and distortion of the cornea that can result in significant visual loss and may lead to the need for a corneal transplant.” states Dr. Tom Tooma, founder of NVISION Eye Centers. “NVISION surgeons are treating patients who are suffering from progressive keratoconus. We are excited to offer a long term solution to our patients with this condition.”
The announcement follows the recent approval that Avedro, Inc., an ophthalmic pharmaceutical and medical device company, has received from the U.S. Food and Drug Administration (FDA).
ABOUT NVISION EYE CENTERS: NVISION Eye Centers is one of the largest providers of LASIK and cataract surgery in the U.S., with 26 centers in California, Nevada, Oregon, Arizona and Toronto, Canada. An innovative leader in ophthalmology, NVISION is dedicated to providing the best patient experience through the use of the latest technology and treatment by the most talented and experienced surgeons in the industry. NVISION was founded in 2010 by Tom Tooma, M.D., one of the earliest pioneers of LASIK who has performed more than 100,000 procedures throughout his esteemed career. With more than 1,900 eye doctors referring their patients and trusting their own eyes to NVISION surgeons, NVISION Eye Centers is the Eye Doctors' #1 Choice®. For more information, visit www.NVISIONCenters.com or call (877) 455-9942.
